Key Takeaways
- • Exponent (NASDAQ: EXPO) trades at $68.30, having delivered a 9.09% earnings surprise with Q2 2026 EPS of $0.60 versus $0.55 expected, demonstrating earnings growth that exceeds consensus estimates.
- • Wall Street analysts project 25.65% upside potential with a consensus 2026 price target of $81–$84, though recent analyst actions show mixed sentiment with UBS lowering its target from $75 to $72 in late July.
- • The company reported Q2 revenue of $171.6M with a 3.34% revenue surprise; trailing twelve-month revenue stands at $567.13M with strong profitability metrics including 19.71% profit margin and 31.20% return on equity.
- • EXPO trades at a trailing P/E of 29.64x on TTM EPS of $2.23, positioning it above broader market multiples; current market capitalization is $3.13 billion with a 52-week trading range of $51.91–$81.95.
- • The stock carries a consensus HOLD rating from multiple analysts with a 1.83% dividend yield ($1.23 forward dividend); next earnings announcement scheduled for October 29, 2026.
Summary
Exponent, Inc. (NASDAQ: EXPO) traded at $68.30 as of September 22, 2026, following a strong earnings beat in Q2 that reinforced the company's execution trajectory. The company reported earnings per share of $0.60 against analyst expectations of $0.55—a 9.09% surprise—while delivering revenue of $171.6M, which exceeded consensus by 3.34%. These metrics underscore consistent operational performance and position Exponent as a consistent earnings deliverer relative to Wall Street forecasts.
Analyst coverage reflects cautious optimism despite recent mixed signals. Wall Street's consensus price target range of $81–$84 implies approximately 25.65% upside from current trading levels, signaling meaningful valuation appreciation potential. However, recent analyst activity tempers this outlook: UBS maintained its Neutral rating but lowered its price target from $75 to $72 in late July 2026, reflecting concern about valuation or forward guidance. The consensus rating stands at HOLD across major platforms, suggesting analysts view current valuations as fairly priced with limited near-term catalysts.
The company's financial health remains robust. Trailing twelve-month revenue reached $567.13M, while net income available to common shareholders totaled $111.77M, translating to a 19.71% profit margin. Return on equity stands at an elevated 31.20% on a TTM basis, demonstrating efficient capital deployment. However, the stock's trailing P/E ratio of 29.64x sits materially above broader market averages, pricing in sustained earnings growth expectations. Total debt-to-equity stands at 27.97%, indicating moderate leverage, while the company generated $76.95M in levered free cash flow TTM, supporting both shareholder distributions and potential reinvestment.
With a market capitalization of $3.13 billion and a 52-week trading range of $51.91–$81.95, EXPO has demonstrated volatility consistent with its 0.69 five-year beta. The stock's 1.83% dividend yield provides modest income while maintaining growth characteristics. The next earnings announcement is scheduled for October 29, 2026, which will be critical for validating whether recent earnings surprises represent sustainable performance trends or temporary outperformance.
Analyst coverage reflects cautious optimism despite recent mixed signals. Wall Street's consensus price target range of $81–$84 implies approximately 25.65% upside from current trading levels, signaling meaningful valuation appreciation potential. However, recent analyst activity tempers this outlook: UBS maintained its Neutral rating but lowered its price target from $75 to $72 in late July 2026, reflecting concern about valuation or forward guidance. The consensus rating stands at HOLD across major platforms, suggesting analysts view current valuations as fairly priced with limited near-term catalysts.
The company's financial health remains robust. Trailing twelve-month revenue reached $567.13M, while net income available to common shareholders totaled $111.77M, translating to a 19.71% profit margin. Return on equity stands at an elevated 31.20% on a TTM basis, demonstrating efficient capital deployment. However, the stock's trailing P/E ratio of 29.64x sits materially above broader market averages, pricing in sustained earnings growth expectations. Total debt-to-equity stands at 27.97%, indicating moderate leverage, while the company generated $76.95M in levered free cash flow TTM, supporting both shareholder distributions and potential reinvestment.
With a market capitalization of $3.13 billion and a 52-week trading range of $51.91–$81.95, EXPO has demonstrated volatility consistent with its 0.69 five-year beta. The stock's 1.83% dividend yield provides modest income while maintaining growth characteristics. The next earnings announcement is scheduled for October 29, 2026, which will be critical for validating whether recent earnings surprises represent sustainable performance trends or temporary outperformance.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.